Moderate-to-severe Atopic Dermatitis Clinical Trial
Official title:
An Efficacy and Safety Study of JYP0061 Tablets in Adult Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Clinical Trial
The goal of this clinical trial is to evaluate the efficacy and safety of JYP0061 in adult patients with moderate-to-severe atopic dermatitis. The main questions it aims to answer are: - The efficacy of JYP0061 in treating adult patients with moderate-to-severe atopic dermatitis. - The safety profile of JYP0061 when administered to adult patients with moderate-to-severe atopic dermatitis. Participants will: - Be treated with either a low-dose or high-dose of JYP0061. - Undergo efficacy and safety evaluations as stipulated in the trial protocol.
The goal of this clinical trial is to assess JYP0061 for efficacy and safety in adult patients with moderate-to-severe atopic dermatitis. The main objectives it aims to address are the determination of the drug's therapeutic effect and its safety profile in this patient population. Upon providing written informed consent after being briefed on the study details and potential risks, participants will enter a screening period of up to 4 weeks to confirm their eligibility. The main tasks for participants will include: - Being randomized to receive either a low-dose or high-dose of JYP0061. - Completing a treatment course of 12 weeks. - Undergoing efficacy and safety assessments as prescribed by the study's protocol. Following the treatment phase, all participants, whether they have completed the treatment course on schedule or have discontinued early, will be monitored for an additional 4 weeks to further evaluate safety post-treatment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03054428 -
Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
|
Phase 3 | |
| Active, not recruiting |
NCT05899816 -
A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)
|
Phase 3 | |
| Recruiting |
NCT04893707 -
The Study of CM310 in Patients With Atopic Dermatitis
|
Phase 2 | |
| Completed |
NCT03985943 -
Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
|
Phase 3 | |
| Completed |
NCT03989349 -
Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
|
Phase 3 | |
| Recruiting |
NCT04921345 -
Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis
|
Phase 2 | |
| Completed |
NCT04893941 -
Dose Escalation Trial of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis (AD)
|
Phase 1/Phase 2 | |
| Completed |
NCT04444752 -
A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis
|
Phase 2 | |
| Completed |
NCT05203380 -
Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis
|
||
| Withdrawn |
NCT05056779 -
Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable
|
Phase 3 | |
| Active, not recruiting |
NCT05590585 -
Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial
|
Phase 4 | |
| Completed |
NCT04805411 -
Subcutaneously CM310/Placebo in Patients With Moderate-to-Severe Atopic Dermatitis (AD)
|
Phase 2 | |
| Recruiting |
NCT05186922 -
The Study of CM326 in Patients With Moderate-to-severe Atopic Dermatitis
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03057860 -
TREATgermany: German National Clinical Registry for Patients With Moderate-to-severe Atopic Dermatitis
|
||
| Active, not recruiting |
NCT03989206 -
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis
|
Phase 3 | |
| Recruiting |
NCT05671432 -
The Study of CM326 in Moderate-to-severe Atopic Dermatitis
|
Phase 2 | |
| Terminated |
NCT05984784 -
A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)
|
Phase 1/Phase 2 | |
| Completed |
NCT05017480 -
A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China
|
Phase 2 |